Laddar...
Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma
PURPOSE: Copy number alterations have been shown to be involved in melanoma pathogenesis. The randomized, phase III clinical trial E2603: carboplatin, paclitaxel, +/− sorafenib (CP vs. CPS) offers a large collection of tumor samples to evaluate association of somatic mutations, genomic alterations,...
Sparad:
| I publikationen: | Clin Cancer Res |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4821426/ https://ncbi.nlm.nih.gov/pubmed/26307133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1162 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|